Epidemiology and Biomarker Study in Alzheimer's Disease
Eli Lilly and Company
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- acronym
- ANCHOR-AD
- status
- RECRUITING
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 3400
- sponsor
- Eli Lilly and Company
- conditions
- Alzheimer Disease
- interventions
- OTHER: P-tau217 Test
- start date
- 2025-08-25
- start date type
- ACTUAL
- primary completion date
- 2033-07-01
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT07142954
- Published
- Aug 27, 2025
- Updated
- Jul 7, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT07142954
- Categories
- Alzheimer Disease
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials